These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 20811146)

  • 1. A thermodynamic model of bone remodelling: the influence of dynamic loading together with biochemical control.
    Klika V; Marsik F
    J Musculoskelet Neuronal Interact; 2010 Sep; 10(3):220-30. PubMed ID: 20811146
    [TBL] [Abstract][Full Text] [Related]  

  • 2. RANK/RANKL/OPG role in distraction osteogenesis.
    Pérez-Sayáns M; Somoza-Martín JM; Barros-Angueira F; Rey JM; García-García A
    Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2010 May; 109(5):679-86. PubMed ID: 20163972
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanical stimulation effects on functional end effectors in osteoblastic MG-63 cells.
    Saunders MM; Taylor AF; Du C; Zhou Z; Pellegrini VD; Donahue HJ
    J Biomech; 2006; 39(8):1419-27. PubMed ID: 15953606
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Osteoblast-osteoclast interaction mechanisms].
    Riancho JA; Delgado-Calle J
    Reumatol Clin; 2011 Sep; 7 Suppl 2():S1-4. PubMed ID: 21924211
    [TBL] [Abstract][Full Text] [Related]  

  • 5. DU145 human prostate cancer cells express functional receptor activator of NFkappaB: new insights in the prostate cancer bone metastasis process.
    Mori K; Le Goff B; Charrier C; Battaglia S; Heymann D; Rédini F
    Bone; 2007 Apr; 40(4):981-90. PubMed ID: 17196895
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Key roles of the OPG-RANK-RANKL system in bone oncology.
    Baud'huin M; Duplomb L; Ruiz Velasco C; Fortun Y; Heymann D; Padrines M
    Expert Rev Anticancer Ther; 2007 Feb; 7(2):221-32. PubMed ID: 17288531
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A theoretical model for simulating effect of parathyroid hormone on bone metabolism at cellular level.
    Wang Y; Qin QH; Kalyanasundaram S
    Mol Cell Biomech; 2009 Jun; 6(2):101-12. PubMed ID: 19496258
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biology of RANK, RANKL, and osteoprotegerin.
    Boyce BF; Xing L
    Arthritis Res Ther; 2007; 9 Suppl 1(Suppl 1):S1. PubMed ID: 17634140
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Functions of RANKL/RANK/OPG in bone modeling and remodeling.
    Boyce BF; Xing L
    Arch Biochem Biophys; 2008 May; 473(2):139-46. PubMed ID: 18395508
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The OPG/RANKL/RANK system and bone resorptive disease].
    Liu JZ; Ji ZL; Chen SM
    Sheng Wu Gong Cheng Xue Bao; 2003 Nov; 19(6):655-60. PubMed ID: 15971575
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Microrough implant surface topographies increase osteogenesis by reducing osteoclast formation and activity.
    Lossdörfer S; Schwartz Z; Wang L; Lohmann CH; Turner JD; Wieland M; Cochran DL; Boyan BD
    J Biomed Mater Res A; 2004 Sep; 70(3):361-9. PubMed ID: 15293309
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Melatonin and bone status].
    Ostrowska Z; Wołkowska-Pokrywa K; Kos-Kudła B; Swietochowska E; Marek B; Kajdaniuk D
    Pol Merkur Lekarski; 2006 Oct; 21(124):389-93. PubMed ID: 17205785
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical applications of RANK-ligand inhibition.
    Romas E
    Intern Med J; 2009 Feb; 39(2):110-6. PubMed ID: 19356186
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The osteoprotegerin/RANK/RANKL system: a bone key to vascular disease.
    D'Amelio P; Isaia G; Isaia GC
    J Endocrinol Invest; 2009; 32(4 Suppl):6-9. PubMed ID: 19724159
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Wnt pathway and IL-17: novel regulators of joint remodeling in rheumatic diseases. Looking beyond the RANK-RANKL-OPG axis.
    Daoussis D; Andonopoulos AP; Liossis SN
    Semin Arthritis Rheum; 2010 Apr; 39(5):369-83. PubMed ID: 19095294
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [New pathophysological relevant metabolic pathways in osteoporosis. Future innovative therapies?].
    Neumann E
    Z Rheumatol; 2006 Sep; 65(5):400, 402-6. PubMed ID: 16924451
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Bone remodeling: a role in bone homeostasis].
    Endo I; Matsumoto T
    Nihon Rinsho; 2009 May; 67(5):873-8. PubMed ID: 19432103
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [New paradigms in the regulation of bone metabolism].
    Rosa-Rañal M; de la Cruz DA; Lorena-Rubio Y; Larrea F
    Rev Invest Clin; 2001; 53(4):362-9. PubMed ID: 11599485
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interactive effect of interleukin-6 and prostaglandin E2 on osteoclastogenesis via the OPG/RANKL/RANK system.
    Liu XH; Kirschenbaum A; Yao S; Levine AC
    Ann N Y Acad Sci; 2006 Apr; 1068():225-33. PubMed ID: 16831922
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Osteoprotegerin and its ligand: A new paradigm for regulation of osteoclastogenesis and bone resorption.
    Aubin JE; Bonnelye E
    Medscape Womens Health; 2000 Mar; 5(2):5. PubMed ID: 10792853
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.